Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2720]

ClarIDHy: Targeted therapy ivosidenib for advanced cholangiocarcinoma

Prof Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York City...

ClarIDHy: Targeted therapy ivosidenib for advanced cholangiocarcinoma ( Prof Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York City, USA )

Bladder cancer: Latest advances in targeted therapies and precision medicine...

Dr Javier Puente, Prof Maria De Santis, Dr Yohann Loriot, Dr Eva Comperat and...

Bladder cancer: Latest advances in targeted therapies and precision medicine from ESMO 2019 ( Dr Javier Puente, Prof Maria De Santis, Dr Yohann Loriot, Dr Eva Comperat and Dr Michiel Van der Heijden )

Latest developments in metastatic prostate cancer from ESMO 2019

Prof Nick James and Prof Nicholas Mottet

Latest developments in metastatic prostate cancer from ESMO 2019 ( Prof Nick James and Prof Nicholas Mottet )

Role of biomarkers, targeted therapy and tumour mutations in the landscape of...

Prof Petros Grivas and Dr Michiel Van der Heijden

Role of biomarkers, targeted therapy and tumour mutations in the landscape of bladder cancer ( Prof Petros Grivas and Dr Michiel Van der Heijden )

Targeted therapy ivosidenib shows clinical benefit in cholangiocarcinoma

Prof Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York City...

Targeted therapy ivosidenib shows clinical benefit in cholangiocarcinoma ( Prof Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York City, USA )

Comment: Targeted therapy ivosidenib in cholangiocarcinoma

Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK

Comment: Targeted therapy ivosidenib in cholangiocarcinoma ( Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK )

Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019

Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith

Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019 ( Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith )

D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk...

Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands

D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk patients in CASSIOPEIA ( Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands )

Comparative effectiveness of lenalidomide, bortezomib, and their combinations...

Dr Peter Barth - Rhode Island Hospital, Philadelphia, USA

Comparative effectiveness of lenalidomide, bortezomib, and their combinations for elderly myeloma patients ( Dr Peter Barth - Rhode Island Hospital, Philadelphia, USA )

Twice-weekly vs once-weekly Krd in early relapsed refractory multiple myeloma

Prof Xavier Leleu - CHU la Miletrie, Poitiers, France

$Twice-weekly vs once-weekly Krd in early relapsed refractory multiple myeloma ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )$

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma

Prof Xavier Leleu - CHU la Miletrie, Poitiers, France

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )

Real-world use of carfilzomib therapy among patients with existing...

Prof Xavier Leleu - CHU la Miletrie, Poitiers, France

Real-world use of carfilzomib therapy among patients with existing cardiovascular medical history ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )

More from ecancer